First Financial Corp IN Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

First Financial Corp IN decreased its position in Eli Lilly and Company (NYSE:LLY) by 6.9% in the first quarter, Holdings Channel reports. The firm owned 4,408 shares of the company’s stock after selling 329 shares during the period. Eli Lilly and Company accounts for 1.7% of First Financial Corp IN’s investment portfolio, making the stock its 8th largest holding. First Financial Corp IN’s holdings in Eli Lilly and Company were worth $3,429,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hoxton Planning & Management LLC raised its stake in Eli Lilly and Company by 5.4% in the first quarter. Hoxton Planning & Management LLC now owns 1,128 shares of the company’s stock worth $878,000 after buying an additional 58 shares in the last quarter. Sarasin & Partners LLP grew its stake in Eli Lilly and Company by 11.4% during the 1st quarter. Sarasin & Partners LLP now owns 275,824 shares of the company’s stock worth $214,580,000 after buying an additional 28,335 shares during the last quarter. Evanson Asset Management LLC increased its holdings in shares of Eli Lilly and Company by 5.3% during the first quarter. Evanson Asset Management LLC now owns 1,347 shares of the company’s stock valued at $1,048,000 after acquiring an additional 68 shares in the last quarter. Dynamic Advisor Solutions LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the first quarter. Dynamic Advisor Solutions LLC now owns 15,381 shares of the company’s stock worth $11,966,000 after buying an additional 417 shares during the last quarter. Finally, Fermata Advisors LLC increased its position in shares of Eli Lilly and Company by 27.8% in the 1st quarter. Fermata Advisors LLC now owns 1,113 shares of the company’s stock valued at $866,000 after acquiring an additional 242 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.1 %

Shares of LLY traded down $0.86 during mid-day trading on Wednesday, reaching $903.75. The company’s stock had a trading volume of 723,052 shares, compared to its average volume of 2,929,059. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $909.42. The stock has a market cap of $858.93 billion, a PE ratio of 133.11, a price-to-earnings-growth ratio of 1.97 and a beta of 0.36. The company’s 50 day moving average is $804.54 and its 200 day moving average is $734.18.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.62 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Wall Street Analysts Forecast Growth

Several analysts have commented on LLY shares. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Jefferies Financial Group increased their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday. Finally, JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $812.72.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the sale, the insider now owns 98,554,195 shares in the company, valued at $79,730,343,755. The disclosure for this sale can be found here. Insiders have sold 789,704 shares of company stock valued at $672,385,964 in the last ninety days. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.